Clinical Faculty

Frits van Rhee, M.D., Ph.D. MRCP (UK), FRCPath
Professor of Medicine, Director of Clinical Research - Myeloma Institute

Research Interest: Immunotherapy
M.D. Erasmus University of Rotterdam, Netherlands
Ph.D. University of London
Visiting Associate at National Institutes of Health, 8/96 -5/98
Fellow in Hematology & Research Fellow, Hammersmith Hospital & Royal Postgraduate Medical School, London, UK, 6/92 - 8/96
Registrar Fellow in Hematology, John Radcliffe University Hospital, Oxford, UK, 2/91 - 5/92
Registrar Fellow in Hematology, University Hospital, Nottingham, UK, 2/90 - 1/91
Residencies from 8/86 to 2/90 at Queen Elizabeth Hospital in Gateshead, UK and Macclesfiedl District General Hospital, Macclesfield, UK

Selected Publications:

Shi J, Tricot G, Szmania S, Malaviarachchi P, Rosen N, Garg T, Malaviarachchi P, Moreno A, Dupont B, Hsu K, Baxter-Lowe L, Cottler-Fox M, Shaughnessy J, Barlogie B, van Rhee F.  Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Brit J Haematol. 2008; 143: 641-653.  PMID: 18950462.

van Rhee F, Dhodapkar M, Shaughnessy JD, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath J, Barlogie B. First thalidomide clinical trial in multiple myeloma:  a decade later. Blood. 2008; 112: 1035-38. PMID: 18502827.

Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B and van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myeloma. Blood. 2008; 111: 1309-1317. PMID: 17947507.

van Rhee F. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients? Nat Clin Pract Oncol. 2008; 5: 70-1. PMID: 17984985.

van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy Jr JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007; 110:  827-32. PMID: 17416735.

Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Huang Y, Moreno A, Thuro B, Mellenhorst J, Barrett  J, Shaughnessy  J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007; 30: 847-854. PMID: 18049337.

van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy JD, Tricot G.  NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005; 105: 3939-44. PMID: 15671442.